GTCbio is proud to present the 3rd Metabolomics - Advances & Applications in Human Disease Conference, which will be part of The Genomics & Big Data Summit and takes place May 25-26, 2016 in Boston, MA.
There is still significant human variability in metabolite identification for targets and pathways. These challenges affect the advancement in biomarker development, mass spectrometry-cased imaging, big data, and the application of metabolomics for drug discovery and development.
Join us for an event that presents new research and offers networking opportunities with the researchers and scientists who are working on developing clinical assays, connecting the metabolome and the genome, and establishing common quality standards for experimental data
I. Advances in Metabolite Markers - Discovery and Validation II. Imaging and Computational Approaches to Assessing the Metabolome III. Metabolite Identification - Targets and Pathways IV. Bioinformatics for Metabolomics: Current Status and Future Directions V. Translating Metabolomics Discoveries in Clinical Practice We hope to see you there! Conference Dates: May 25-26, 2016 Conference Link: http://www.gtcbio.com/metabolomics
On behalf of GTCbio and the 2016 Advisory Board, you are invited to the CRISPR & Genome Engineering Conference which takes place May 26-27, 2016 in Boston, MA. This meeting is part of The Genomics & Big Data Summit and will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and discuss the most recent advances in CRISPR & Genome Engineering.
Leading researchers will present on hot topics such as: therapeutic applications of CRISPR and genome engineering, discovery and mechanisms of CRISPR systems, and will discuss updates on current CRISPR technologies and techniques. In addition to scientific talks, dedicated networking sessions will allow attendees to better dialogue on how CRISPR & Genome
Engineering will continue to impact biomedical research.
I. Therapeutic Applications of CRISPR & Genome Engineering II. Advances in CRISPR-Cas9 Specificity III. Discovery and Mechanisms of CRISPR Systems IV. Update: Current CRISPR Technologies & Techniques V. CRISPR Regulation of Gene Expression We look forward to seeing you at the conference! Conference Dates: May 26-27, 2016 Conference Link: http://www.gtcbio.com/CRISPR
SMi will present their inaugural conference on Alzheimer’s Disease 2016, which is one of the most threatening diseases that accompanies age, yet formidably mysterious in biology.
This conference will cover: Pre-clinical assessment criteria for AD diagnosis such as risk profiling, population group assessment and stages of AD progression. How do external stimuli play influence studies and outcome?
Furthermore, emerging frontiers in biomarker development to aid more accurate diagnosis and tracking of tau-mediated neuronal death will help further drug development as well as providing more answers into how AD occurs, and most importantly when.
The conference will gather leading researchers and clinical managers to discuss models, diagnostic imaging and novel therapeutic platforms.
For more info visit: http://www.alzheimers-conference.com/bioscreening
SMi Group are thrilled to present the 2nd annual Lyophilization USA conference, returning to Iselin, New Jersey on April 27th & 28th 2016.
With an increase in contract services, combination products and innovative drug delivery devices, growing demand for lyophilization equipment and lyophilized biopharmaceuticals has contributed to a projected rise in market growth from US $2.0 billion in 2013 to US $4.8 billion by 2020.
While pharmaceutical companies are still dedicating research efforts on freeze drying technologies, commerciality of scaling up and homogeneity of product quality remain top concerns.
Lyophilization USA 2016 will gather leading market experts to discuss the latest cutting edge developments in freeze drying as well as solutions to on-going industry challenges. The packed agenda features a mix of case study led presentations, panel debates, interactive workshops and keynote addresses that have been tailored for an audience of professionals working in pharmaceutical lyophilization from formulation development through to production and quality assurance.
Featured Speakers Include:
Jim Searles, Technical Fellow, Global Technical Services, Pfizer
Mark Yang, Director, Genzyme
Evgenyi Shalaev, Research Investigator, Allergan
Sune Andersen, Principal Scientist Drying Processes, Novo Nordisk A / S
Vineet Kumar, Senior Scientist, Johnson & Johnson
Ralph Tarantino, Pharmaceutical Consultant & Principal, Steritech Solutions LLC
Stuart Wang, Senior Scientist, Protein Process Development, Biogen Idec
Jamie Tsung, Principal Scientist, Momenta Pharmaceuticals
Why You Should Attend:
Define CQAs and QbD for a smooth lyophilization program – bridging upstream and downstream
Learn about new technologies to accelerate lyophilization process and stabilize complex biologics products
Thrive on product quality control and assurance during mass production and tech transfer
‘Dry fast and smart’ – develop a commercially viable lyophilization cycle
Benchmark your strategies against peers’ and industry experts’ to ensure a sustainable drug development program and pipeline
Register online at http://www.lyophilization-usa.com/bioscreening
Emulating from the success of its 2015 sell-out show, SMi Group is delighted to announce the return of the 3rd annual conference and exhibition: Pre-Filled Syringes - East Coast, taking place on April 25th – 26th 2016 in Iselin, New Jersey, USA.With the growing demand for biologics and ready-to-administer (RTA) syringes, recent reports have predicted the global pre-filled syringes (PFS) market to reach $6.6bn by 2020. While we have witnessed booming investments in PFS, the industry still needs to overcome a number of hurdles to commercialize this delivery platform.Through a combination of powerful keynote addresses, topical debate and interactive workshops, Pre-Filled Syringes East Coast will once again play host to an audience of senior scientists, device manufacturers and PFS market professionals, providing a focal point to discuss the latest innovations and developments in pre-filled syringes; as well as honing in on industry challenges and regulatory compliance.The expert speaker line-up for 2016 includes:Stephen Barat, Executive Director, Non-Clinical & Translational Sciences, Safety Assessment & Bioanalysis, AllerganRavi S. Harapanhalli Ph.D., Principal, FDAPharma Consulting LLCMathias Romacker, Senior Director, Device Strategy, PfizerDr. Paolo Mangiagalli, Senior Director, Head PFS Platform, SanofiKen Wong, Deputy Director, MTech/ Process Technology – Extractables & Leachables, Sanofi PasteurCarsten Worsoe, Principal Scientist, CMC Analytical Support, Novo Nordisk A/SDr. Shawn Davis, Principal Engineer, Device Strategy, AmgenMohammed Umar, Principal Technical Manager, Quality Engineering, GenentechJason Lipman, Associate Director, Regulatory Affairs, Medical Devices & Combination Products, Janssen R&D, LLCEvent Highlights:Discover how to eliminate extractables and leachables (E&L) through a case study driven presentation from MerckHear how Eli Lilly give the PFS a human touch – incorporating human factor engineering into a patient-centric deviceEnsure commercial competitiveness of PFS as a drug deviceAssess trends of combination products and impacts on PFSLearn about the latest cutting edge technological developments in COP and sterilization to accelerate your PFS developmentExclusive post-conference workshops led by Cambridge Consultants on Human Factor Engineering and FDAPharma Cosulting LLC on CMC ConsiderationsFor further details and to download a brochure, visit the website at www.pfsamericas.com/bioscreening
Page 2 of 36
© 2014 Bioscreening.com